Table 1.
The summary of the effects of NaHS in different cancer cell types.
| Cancer types | Cell lines | NaHS doses | Effects on Cancer | References |
|---|---|---|---|---|
| Breast cancer | MCF-7 | 5-20 µM, 500 µM | Inhibition | 14, 112 |
| HCC | HepG2 | 5-20 µM, 1000 µM | Inhibition | 14, 38 |
| HLE | 1000 µM | Inhibition | 38 | |
| PLC/PRF/5 | 100-500 µM | Promotion | 13 | |
| SMMC-7721 | 10-100 µM | Promotion | 126 | |
| Huh-7 | 400-1000 µM | Inhibition | ||
| Thyroid cancer | TPC-1 TT |
10-50 µM | Promotion | 127 |
| ARO | 200 µM | Inhibition | ||
| NSCLC | A549 A549/DDP |
800 µM | Inhibition | 113, 128 |
| Esophageal carcinoma | EC 109 | 200-1000 µM | Promotion | 18, 175 |
| Glioma | C6 | 100-1600 µM | Promotion/Inhibition | 153, 179 |
| Gastric cancer | SGC 7901 | 200-800 µM | Inhibition | 39 |
| Oral SCC | GMN Cal-27 WSU-HN6 |
200-1000 µM | Promotion | 172, 178 |
| Multiple Myeloma | NCI-H929 | 250-1000 µM | Promotion | 174 |
| Bladder Cancer | EJ | 400 µM | Promotion | 188 |
| Colon Cancer | HCT 116 SW480 |
50 - 200 µM | Promotion | 173, 199 |
| SW480 | 1000 µM | Inhibition |